Methicillin-resistant Staphylococcus aureus (MRSA)
We’re thrilled to announce a groundbreaking development in the fight against antibiotic-resistant bacteria and the health challenges they pose. Naranhay Ltd. has successfully formulated a proprietary blend of phytocannabinoids with potent pharmacological activity, offering a promising solution to this pressing global issue.
Our dedicated team has meticulously crafted this innovative blend, harnessing the power of nature to combat antibiotic resistance and its associated health conditions. With a focus on efficacy and safety, our blend stands poised to revolutionize the landscape of bacterial infection treatment.
But our commitment doesn’t stop there. At Naranhay Ltd., we understand the importance of navigating regulatory frameworks across different global regions. That’s why our team is diligently considering regulatory aspects to ensure smooth marketing and distribution of our pipeline projects.
We’re not just aiming to enter the market; we’re strategizing to do so in a manner that maximizes impact and sustainability. By prioritizing revenue generation, we’re building a self-sustainable system that spans from research and development to market delivery.
At Naranhay Ltd., we’re not just developing products; we’re pioneering solutions. Join us in our mission to combat antibiotic resistance and usher in a healthier future for all. Together, we can make a difference. Stay tuned for more updates as we progress on this exciting journey!
Porphyromonas gingivalis (PG)
Naranhay Ltd. is proud to unveil its revolutionary proprietary blend of phytocannabinoids, meticulously formulated to combat the growing menace of antibiotic-resistant bacteria and its associated health complications. At the forefront of our innovation lies the recognition of Porphyromonas gingivalis (PG), a Gram-negative oral anaerobe implicated in the onset and progression of periodontitis—an inflammatory condition wreaking havoc on the supportive tissues of teeth, ultimately culminating in tooth loss.
PG, as the primary instigator in chronic periodontitis, has now been identified within the brain tissues of Alzheimer’s disease patients, marking a significant breakthrough in understanding the interplay between oral health and cognitive decline. Furthermore, the presence of toxic proteases, known as gingipains, derived from PG, has been detected in the brains of Alzheimer’s patients, with their levels correlating strongly with tau and ubiquitin pathology—a pivotal revelation shedding light on the intricate mechanisms underpinning neurodegenerative disorders.
With our proprietary blend of phytocannabinoids exhibiting robust pharmacological activity, Naranhay Ltd. aims to address this nexus between oral bacteria-induced inflammation and neurodegeneration. By leveraging cutting-edge research and development, we aspire to provide a multifaceted solution that not only combats periodontitis but also offers potential therapeutic avenues for mitigating the cognitive decline associated with Alzheimer’s disease. Together, we embark on a journey towards healthier futures, bridging the gap between oral and neurological health with innovation and compassion.
Pseudomonas aeruginosa (PA)
Naranhay Ltd. proudly introduces an innovative anti-Pseudomonas aeruginosa cream infused with cannabis, offering a promising solution for wound care. Developed meticulously to combat the challenges posed by Pseudomonas aeruginosa infections, our groundbreaking cream combines the therapeutic properties of cannabinoids with advanced medical science.
The application process is straightforward yet effective: following standard cleaning procedures, the cannabinoid-infused cream is gently applied to the surface of the wound. Subsequently, a specialized bandage is carefully secured over the treated area, ensuring optimal absorption and sustained release of the therapeutic compounds. It is crucial to adhere to the prescribed regimen, replacing the bandage daily to maintain cleanliness and maximize the cream’s efficacy.
At Naranhay Ltd., we remain committed to pushing the boundaries of medical innovation, delivering safe and effective solutions to address complex healthcare challenges. With our anti-Pseudomonas aeruginosa cream, patients can now benefit from the synergistic effects of cannabis-derived compounds, paving the way for enhanced wound healing and improved outcomes. Join us in revolutionizing wound care with science, compassion, and unwavering dedication to excellence.